Boston Cell Standards

Boston Cell Standards is a private diagnostics and life science tools company focused on improving the accuracy, reproducibility, and standardization of immunohistochemistry (IHC) testing used in cancer diagnosis and treatment selection. The company develops quantitative reference materials and on-slide controls, including its IHCalibrators and IHControls products, to help pathology laboratories measure assay sensitivity, verify staining performance, and reduce inter-laboratory variability. Its products are designed for anatomic pathology and companion-diagnostic style workflows, particularly in oncology biomarkers such as HER2, estrogen receptor, and progesterone receptor. Boston Cell Standards has received FDA 510(k) clearance for its HER2/ER/PR IHControls panel and has partnered with Visiopharm to combine calibration materials with image analysis software for higher-quality IHC assay control. Overall, the company is best understood as a diagnostics quality-assurance platform company rather than a therapeutic drug developer.